Free Trial
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

10x Genomics logo
$21.07 +0.15 (+0.72%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$21.01 -0.06 (-0.30%)
As of 05/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About 10x Genomics Stock (NASDAQ:TXG)

Advanced

Key Stats

Today's Range
$20.40
$21.11
50-Day Range
$16.69
$26.08
52-Week Range
$8.06
$26.44
Volume
2.11 million shs
Average Volume
2.77 million shs
Market Capitalization
$2.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.46
Consensus Rating
Hold

Company Overview

10x Genomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

TXG MarketRank™: 

10x Genomics scored higher than 38% of companies evaluated by MarketBeat, and ranked 709th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 1 strong buy rating, 5 buy ratings, 9 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for 10x Genomics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    10x Genomics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about 10x Genomics' stock forecast and price target.
  • Earnings Growth

    Earnings for 10x Genomics are expected to grow in the coming year, from ($0.88) to ($0.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 10x Genomics is -123.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 10x Genomics is -123.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    10x Genomics has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.95% of the float of 10x Genomics has been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 6.12.
  • Change versus previous month

    Short interest in 10x Genomics has recently decreased by 1.37%, indicating that investor sentiment is improving.
  • Dividend Yield

    10x Genomics does not currently pay a dividend.

  • Dividend Growth

    10x Genomics does not have a long track record of dividend growth.

  • News Sentiment

    10x Genomics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for 10x Genomics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 12 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $902,695.00 in company stock.

  • Percentage Held by Insiders

    8.84% of the stock of 10x Genomics is held by insiders.

  • Percentage Held by Institutions

    84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 10x Genomics' insider trading history.
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TXG Stock News Headlines

What is “gold skimming”?
Former $900 million hedge fund manager Larry Benedict has developed a strategy he calls Gold Skimming - a way to target cash payouts from gold markets without buying a single ounce, mining stock, or ETF. With a reported 73% win rate across 19 trades and potential payouts of $2,975, $3,781, and $6,786 in a single day, Benedict has put together a free step-by-step walkthrough showing how it works whether gold climbs or pulls back.tc pixel
10x Genomics (TXG) Q1 2026 Earnings Transcript
10x Genomics (NASDAQ:TXG) CEO Sells $122,800.00 in Stock
See More Headlines

TXG Stock Analysis - Frequently Asked Questions

10x Genomics' stock was trading at $16.31 at the beginning of 2026. Since then, TXG shares have increased by 29.2% and is now trading at $21.07.

10x Genomics (NASDAQ:TXG) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.19. 10x Genomics's revenue was up 9.4% on a year-over-year basis.
Read the conference call transcript
.

10x Genomics (TXG) raised $370 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 10,000,000 shares at a price of $36.00-$38.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

Top institutional investors of 10x Genomics include Sumitomo Mitsui Trust Group Inc. (4.00%), Amova Asset Management Americas Inc. (4.00%), Dimensional Fund Advisors LP (1.60%) and Quantedge Capital Pte Ltd (0.33%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Justin J Mcanear, James Wilbur and Alan Mateo.
View institutional ownership trends
.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/07/2026
Today
5/13/2026
Bank of America Global Healthcare Conference 2026
5/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:TXG
CIK
1770787
Fax
N/A
Employees
1,240
Year Founded
2012

Price Target and Rating

High Price Target
$32.00
Low Price Target
$14.00
Potential Upside/Downside
+6.6%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.54 million
Net Margins
-3.55%
Pretax Margin
-3.01%
Return on Equity
-2.86%
Return on Assets
-2.23%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.90
Quick Ratio
4.09

Sales & Book Value

Annual Sales
$642.82 million
Price / Sales
4.19
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.37 per share
Price / Book
3.31

Miscellaneous

Outstanding Shares
127,750,000
Free Float
116,459,000
Market Cap
$2.69 billion
Optionable
Optionable
Beta
2.05

Social Links

Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:TXG) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners